Last checked at 25 May 2021 10:00
25 May 2021
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Posting of Annual Report and Notice of AGM
Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that its Annual Report and Accounts for the year ended 31 December 2020 and the Notice of the 2021 Annual General Meeting are now available on the Company's website, www.avacta.com.
Copies of the Annual Report and Accounts and the Notice of AGM have been posted to shareholders who have elected to receive them in paper form.
The Annual General Meeting will be held on Monday, 28 June 2021 at 10.00 a.m. at the offices of Walker Morris LLP at 33 Wellington Street, Leeds LS1 4DL.
In the light of the Coronavirus pandemic, shareholders are strongly urged to appoint the chairman of the Meeting as his or her proxy as, given the Coronavirus situation and current Government advice on public gatherings, attendance in person is not advised.
To enable shareholders to raise any questions they may have prior to the AGM, the Company will be providing a Business Update webinar led by Alastair Smith, Chief Executive Officer which will take place at 10:00am on Monday 21 June 2021.
The webinar is open to all shareholders and will consist of a presentation followed by a Q&A session, held on the Investor Meet Company platform. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Shareholders can sign up to Investor Meet Company for free and then click "Add to meet" Avacta Group via the following link to join the webinar:
https://www.investormeetcompany.com/avacta-group-plc/register-investor
Shareholders who already follow Avacta Group plc on the Investor Meet Company platform will automatically be invited.
-Ends -
For further information from Avacta Group plc, please contact:
Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer Michael Vinegrad, Group Communications Director | Tel: +44 (0) 844 414 0452 www.avacta.com
| |
Stifel Nicolaus Europe Limited (Nomad and Sole Corporate Broker) |
Tel: +44 (0) 207 710 7600 | |
Nicholas Moore / Nick Adams / Fred Walsh / Ben Maddison | www.stifel.com | |
FTI Consulting (Financial Media and IR)Simon Conway / Stephanie Cuthbert | Tel: +44(0) 203 727 1000Avacta.LS@fticonsulting.com | |
Zyme Communications (Trade and Regional Media) Katie Odgaard
|
Tel: +44 (0)7787 502 947 katie.odgaard@zymecommunications.com
| |
About Avacta Group plc - https://www.avacta.com
Avacta Group is developing novel cancer immunotherapies and powerful diagnostics based on its two proprietary platforms - Affimer® biologics and pre|CISION™ tumour targeted chemotherapies.
The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets, such as diagnostics and therapeutics, worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken to generate new antibodies and the reliance on an animal's immune response; poor specificity in many cases; their large size, complexity and high cost of manufacture.
Avacta's pre|CISION targeted chemotherapy platform releases active chemotherapy in the tumour, which limits the systemic exposure that causes damage to healthy tissues, and thereby improves the overall safety and therapeutic potential of these powerful anti-cancer treatments.
The Group comprises two divisions: The therapeutics development activities are based in Cambridge, UK and the Group is generating near-term revenues from Affimer reagents for diagnostics, bioprocessing and research, through a separate diagnostics business unit based in Wetherby, UK.
Avacta's Diagnostics Division works with partners world-wide to develop bespoke Affimer reagents for third party products. The Group is also developing an in-house pipeline of Affimer-based diagnostic assays including the AffiDX® SARS-CoV-2 Lateral Flow Rapid Antigen Test and AffiDX® BAMS™ SARS-CoV-2 Assay in partnership with Adeptrix Inc.
Avacta's Therapeutics Division is addressing a critical gap in current cancer treatment - the lack of a durable response to current immunotherapies experienced by most patients. By combining its two proprietary platforms the Group is building a wholly owned pipeline of novel cancer therapies deigned to be effective for all cancer patients. In 2021 Avacta will commence a phase 1 first-in-human, open label, dose-escalation and expansion study of AVA6000 Pro-doxorubicin, the Group's lead pre|CISION™ prodrug, in patients with locally advanced or metastatic selected solid tumours.
Avacta has established drug development partnerships with pharma and biotech, including a research collaboration with ModernaTX,Inc. (formerly Moderna Therapeutics Inc.), a multi-target deal with LG Chem worth up to $400m, a joint venture in South Korea with Daewoong Pharmaceutical focused on cell and gene therapies incorporating Affimer immune-modulators, a partnership with ADC Therapeutics to develop Affimer-drug conjugates and a collaboration with Point Biopharma to develop radiopharmaceuticals based on the pre|CISION™ platform. Avacta continues to actively seek to license its proprietary platforms in a range of therapeutic areas.
To register for news alerts by email go to www.avacta.com/investor-news-email-alerts